PriceTargets.com logo

Beigene - ONC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $318.88
  • Forecasted Upside: 30.21%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$244.90 As of 04/25/2025 05:00 PM ET
▼ -11.26 (-4.40%)

This chart shows the closing price for ONC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMarApr$244.90Closing price on 04/26/25:
Get New Beigene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONC

Analyst Price Target is $318.88
▲ +30.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Beigene in the last 3 months. The average price target is $318.88, with a high forecast of $348.00 and a low forecast of $259.00. The average price target represents a 30.21% upside from the last price of $244.90.

This chart shows the closing price for ONC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
2/254/255/26$144$195$246$297$348Closing price on 04/26/25: $244.90High$348.00Average$318.88Low$259.00




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Beigene.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2025

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/24/2025TD SecuritiesReiterated RatingBuy ➝ Buy$334.00 ➝ $334.00
4/21/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$311.00 ➝ $317.00
4/16/2025GuggenheimReiterated RatingBuy ➝ Buy
4/10/2025GuggenheimReiterated RatingBuy ➝ Buy$348.00 ➝ $348.00
4/7/2025Royal Bank of CanadaInitiated CoverageOutperform$312.00
4/7/2025Royal Bank of CanadaUpgradeModerate Buy$312.00
3/13/2025Sanford C. BernsteinSet Target$259.00
3/3/2025Bank of AmericaUpgradeNeutral ➝ Buy$207.00 ➝ $320.00
2/28/2025GuggenheimReiterated RatingBuy ➝ Buy
2/28/2025JMP SecuritiesSet Target$348.00
2/28/2025MacquarieBoost TargetOutperform ➝ Outperform$259.00 ➝ $313.00
(Data available from 4/27/2020 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2025
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2025
  • 17 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/28/2025
  • 7 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/27/2025

Current Sentiment

  • 7 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Beigene logo
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Read More

Today's Range

Now: $244.90
Low: $244.40
High: $250.82

50 Day Range

MA: $247.84
Low: $206.32
High: $278.38

52 Week Range

Now: $244.90
Low: $141.31
High: $287.88

Volume

488,142 shs

Average Volume

491,171 shs

Market Capitalization

$24.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Beigene?

The following Wall Street sell-side analysts have issued stock ratings on Beigene in the last twelve months: Bank of America Co., Guggenheim, JMP Securities, JPMorgan Chase & Co., Macquarie, Royal Bank of Canada, Sanford C. Bernstein, and TD Securities.
View the latest analyst ratings for ONC.

What is the current price target for Beigene?

0 Wall Street analysts have set twelve-month price targets for Beigene in the last year. Their average twelve-month price target is $318.88, suggesting a possible upside of 30.2%. JMP Securities has the highest price target set, predicting ONC will reach $348.00 in the next twelve months. Sanford C. Bernstein has the lowest price target set, forecasting a price of $259.00 for Beigene in the next year.
View the latest price targets for ONC.

What is the current consensus analyst rating for Beigene?

Beigene currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ONC will outperform the market and that investors should add to their positions of Beigene.
View the latest ratings for ONC.

What other companies compete with Beigene?

Other companies that are similar to Beigene include GSK, Takeda Pharmaceutical, argenx, BioNTech and Summit Therapeutics. Learn More about companies similar to Beigene.

How do I contact Beigene's investor relations team?

Beigene's physical mailing address is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108. The company's listed phone number is 13459494123 and its investor relations email address is ir@beigene.com. The official website for Beigene is beigene.com. Learn More about contacing Beigene investor relations.





Receive Beigene News & Ratings Daily
Sign up to receive the latest news and ratings for Beigene and its competitors with PriceTargets.com’s free daily newsletter.